SIGNED III (forlengelse av FOTS12396)
1. Purpose
The main goal of this project is to increase our understanding about the role of xenobiotics in the development of metabolic diseases. More specifically, our purpose is to understand the mechanisms by which xenobiotics can induce intestinal inflammation and dysfunction, which are critical factors in metabolic diseases.
In the present project we will submit mice to DSS and LPS treatment to induce intestinal inflammation and use Dextran-FITC and carmine to assess intestinal dysfunctions. These investigations will be complemented by tissue collection (small intestine, colon, liver, etc) to assess gene and protein expression and delineate potential molecular mechanisms.
2. Distress
Body weight loss may occur during DSS and LPS treatment. For the other procedures, no pain/disconfort is expected.
3. Expected benefits
By answering our main goal (see 1. Purpose) we will push forward the scientific field and provide new insight into the mechanisms involved in intestinal inflammation. This knowledge will help developing new anti-inflammatory drugs.
4. Number of animals
In total, 480 male mice (C57BL6 strain) may be used in this 4-year project.
5. How to adhere to 3R
The use of animals is unavoidable since we want to study inflammation in the whole intestine (duodenum, jejuneum, ileum and colon) in the context of metabolic diseases. We will use the minimum number of animals required for our analysis and we will monitor closely the well being of the animals
6. Additional information
This project has been previously approved by Mattilsynet (FOTS #12396) and has been delayed (Covid 19). We want here to apply for a new FOTS approval (see e-mail exhanges between Vera Rodas and Jerome Ruzzin in April 2021).
The main goal of this project is to increase our understanding about the role of xenobiotics in the development of metabolic diseases. More specifically, our purpose is to understand the mechanisms by which xenobiotics can induce intestinal inflammation and dysfunction, which are critical factors in metabolic diseases.
In the present project we will submit mice to DSS and LPS treatment to induce intestinal inflammation and use Dextran-FITC and carmine to assess intestinal dysfunctions. These investigations will be complemented by tissue collection (small intestine, colon, liver, etc) to assess gene and protein expression and delineate potential molecular mechanisms.
2. Distress
Body weight loss may occur during DSS and LPS treatment. For the other procedures, no pain/disconfort is expected.
3. Expected benefits
By answering our main goal (see 1. Purpose) we will push forward the scientific field and provide new insight into the mechanisms involved in intestinal inflammation. This knowledge will help developing new anti-inflammatory drugs.
4. Number of animals
In total, 480 male mice (C57BL6 strain) may be used in this 4-year project.
5. How to adhere to 3R
The use of animals is unavoidable since we want to study inflammation in the whole intestine (duodenum, jejuneum, ileum and colon) in the context of metabolic diseases. We will use the minimum number of animals required for our analysis and we will monitor closely the well being of the animals
6. Additional information
This project has been previously approved by Mattilsynet (FOTS #12396) and has been delayed (Covid 19). We want here to apply for a new FOTS approval (see e-mail exhanges between Vera Rodas and Jerome Ruzzin in April 2021).